A new study suggests that GLP-1s, a type of weight-loss drug, may lower the risk of certain cancers. The specific types of cancer that may be affected are not universally agreed upon, but some reports indicate that GLP-1s may reduce the risk of obesity-related cancers. Research appears to be ongoing, with some outlets indicating a potential link between GLP-1s and reduced cancer risk, although the extent and implications of this connection are still being explored.